MYCB1 Group B.V.

MYCB1 Group B.V. is a Dutch healthtech and pharmaceutical group founded in 2017 and based in Amsterdam, with operations in Germany through its subsidiary MYCB1 GmbH.

The company serves as a pharmaceutical cannabis gateway for the German market, focusing on prescription-only, GMP-grade cannabinoid-based medicines. It combines pharmaceutical manufacturing, pharmacy operations, and software-driven healthcare services. The core services of MYCB1 include regulatory infrastructure, GMP/GDP operations, storage, and distribution in Germany, while maintaining brand and commercial control for its partners. The company also offers logistics, manufacturing, and distribution services for pharmacies, along with the production of pharmaceutical active ingredients. Its proprietary real-world data platform, ALETTA®, supports patient-focused care by improving adherence and outcomes for patients under chronic therapy. MYCB1 targets doctors, pharmacists, hospitals, and patients, and has established distribution agreements in Germany and Scandinavia, with ongoing negotiations in Europe, Asia, and Latin America.